Morphine/naltrexone
| Combination of | |
|---|---|
| Morphine sulfate | Opioid |
| Naltrexone | Opioid antagonist |
| Clinical data | |
| Trade names | Embeda |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| (verify) | |
The drug combination morphine/naltrexone (trade name Embeda) is an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain.[2] The active ingredients are morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule II controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated.[1]
King Pharmaceuticals temporarily recalled Embeda in 2011, after complaints from the FDA in regard to King Pharmaceuticals omitting information regarding the potentially fatal reaction if crushed and swallowed and also for making unsubstantiated claims regarding Embeda's reduced abuse potential.[3]
References
[edit]- ^ a b "Embeda- morphine sufate capsule, extended release". DailyMed. 22 January 2010. Retrieved 7 June 2023.
- ^ "Medication guide" (PDF). www.fda.gov.
- ^ Eustice C (15 March 2011). "Chronic Pain Drug Embeda Recalled". About.com. Archived from the original on 15 March 2012.
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |